Our Company
Xellia is a specialty pharmaceutical company focusing on providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions.
Xellia has been wholly owned by Novo Holdings A/S since 2013 and is headquartered in Copenhagen, Denmark. We have three state-of-the-art manufacturing facilities in Denmark, Hungary, and China.
Our Board of Directors
Our Heritage
Our Values
We truly believe that we can only succeed in our purpose through the engagement and expertize of our employees. Our culture is built on four values and four leadership principles which serve as an enabler and reinforcement to our behaviours and actions.
Our Purpose, Goal and ValuesOur Leadership Promise
The Global Anti-infectives Business
The Global Anti-infectives business unit represents the company's legacy. We are a market leader in supplying anti-infective medicines to 500 pharmaceutical customers in over 80 geographical markets.
Xellia’s goal is to demonstrate excellence in innovative development and state-of-the-art manufacturing to meet the demands for anti-infective and critical care therapies for patients around the world
